FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More

 
• By Malcolm Spicer

Agency says "some credible evidence" suggests intake of  EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.

Red heart and a stethoscope on backgrouund - Image

The US Food and Drug Administration will exercise enforcement discretion for five additional qualified health claims for blood pressure and coronary heart disease risk reduction to be used with omega-3 supplements.

The agency announced the decision on 19 June in its response to a citizen petition by the Global Organization for EPA and DHA Omega-3, which sought unqualified health claims for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from HBW Insight